Cerebras Systems, known for accelerating generative artificial intelligence (AI), has collaborated with Mayo Clinic, focusing on the development of large language models (LLMs) for various medical applications.
This multi-year partnership was revealed during the JP Morgan Healthcare Conference in San Francisco, US.
As part of this partnership, Cerebras and Mayo Clinic have already started producing new LLMs to enhance overall patient outcomes and diagnoses.
The collaborative work will further accelerate the delivery of breakthrough insights by integrating Mayo Clinic's longitudinal data repository with Cerebras' generative AI computing capabilities.
Mayo Clinic’s decision to select Cerebras to provide its expertise in crafting and training large-scale, domain-specific generative AI models is in alignment with Mayo Clinic’s goal to establish the first patient-centric healthcare AI.
The first key outcome of this collaboration is the development of a diagnostic model for rheumatoid arthritis (RA).
This model will leverage and combine patient records, DNA, and drug molecule data to better match RA patients with effective treatments.
Both Mayo Clinic and Cerebras look to extend this approach to other diseases.
According to Cerebras, the training of extensive AI models demands substantial computational power, large datasets, and specialised AI knowledge.
To address these needs, Cerebras will utilise its CS-2 system, powered by the WSE-2, which is specifically designed for generative AI, offering a unique blend of top-tier AI computing, software, and expertise.
Cerebras CEO and co-founder Andrew Feldman said: “It is an honour to collaborate with Mayo Clinic, the top-ranked hospital in the nation. With its recognised leadership in delivering medical outcomes, we are uniquely positioned to combine AI and medicine.
“The state-of-the-art AI models we are developing together will work alongside doctors to help with patient diagnosis, treatment planning, and outcome estimation.”
In December 2023, Mayo Clinic in the US entered an agreement to purchase the Ivenix Infusion System from healthcare company Fresenius Kabi.
